沙利度胺与地塞米松联合治疗难治复发性多发性骨髓瘤的疗效观察  

Clinical study on thalidomide combined with dexamethasone in the treatment of refractory or relapsing multiple myeloma

作　　者：韩雨[1] 王成[1] 丁海霞[1] 

机构地区：[1]吉林省肿瘤医院肿瘤内科,长春130012

出　　处：《中国肿瘤临床与康复》2008年第2期129-130,共2页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的观察沙利度胺联合地塞米松治疗难治复发性多发性骨髓瘤的临床疗效。方法12例难治复发性多发性骨髓瘤患者，沙利度胺起始剂量100mg／d，每周增加100mg，最大剂量400mg／d，地塞米松40mg，第1—4天，第9—12天，第17—20天，4周一个疗程，至少观察3个疗程以上。结果完全缓解2例（16．7％），部分缓解6例（50．0％），微小反应2例（16．7％），无反应2例（16．7％），有效8例（66．7％）。结论沙利度胺联合地塞米松对难治复发性多发性骨髓瘤治疗有较好疗效。Objective To observe the curative effect of thalidomide combined with dexamethasone （Thal-Dex） in treatment of refractory or relapsing multiple myeloma. Methods Twelve patients with ad- vanced and refractory relapsing multiple myeloma were treated with Thal-Dex. All of the patients were given thalidomide at the starting dose of 100 mg/d, increasing by 100 mg/d every week till 400 mg/d;dexamethasone 40 mg/d,dl4,dg-12, d17-20 in each cycle, repeated monthly. Results Two of 12 patients had complete remission （CR,16.7%）, 6 of them got partial remission（ PR,50. 0% ） ,2 of them showed minimal response（ MR, 16. 7% ） and 2 had no response （ NR, 16.7% ）, with a total efficacy rate of 66. 7% （ CR ＋ PR）. Conclusion Thalidomide combined with dexamethasone in the treatment of refractory or relapsing multiple myeloma might be effective.

关 键 词：沙利度胺 地塞米松 多发性骨髓瘤 

分 类 号：R733.3[医药卫生—肿瘤] R730.53[医药卫生—临床医学]